Switch to:
Also traded in: Belgium, Germany, Netherlands, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2839.12
GLPGF's Cash to Debt is ranked higher than
57% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. GLPGF: 2839.12 )
Ranked among companies with meaningful Cash to Debt only.
GLPGF' s Cash to Debt Range Over the Past 10 Years
Min: 2.96  Med: 111.74 Max: No Debt
Current: 2839.12
Equity to Asset 0.91
GLPGF's Equity to Asset is ranked higher than
60% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GLPGF: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
GLPGF' s Equity to Asset Range Over the Past 10 Years
Min: 0.46  Med: 0.74 Max: 0.91
Current: 0.91
0.46
0.91
F-Score: 4
Z-Score: 12.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -92.21
GLPGF's Operating margin (%) is ranked higher than
53% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. GLPGF: -92.21 )
Ranked among companies with meaningful Operating margin (%) only.
GLPGF' s Operating margin (%) Range Over the Past 10 Years
Min: -59.16  Med: -27.60 Max: 1.78
Current: -92.21
-59.16
1.78
Net-margin (%) -92.82
GLPGF's Net-margin (%) is ranked higher than
96% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. GLPGF: -92.82 )
Ranked among companies with meaningful Net-margin (%) only.
GLPGF' s Net-margin (%) Range Over the Past 10 Years
Min: -58.19  Med: -15.25 Max: 47.88
Current: -92.82
-58.19
47.88
ROE (%) -19.50
GLPGF's ROE (%) is ranked higher than
91% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. GLPGF: -19.50 )
Ranked among companies with meaningful ROE (%) only.
GLPGF' s ROE (%) Range Over the Past 10 Years
Min: -24.8  Med: -9.47 Max: 17.79
Current: -19.5
-24.8
17.79
ROA (%) -16.03
GLPGF's ROA (%) is ranked higher than
91% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. GLPGF: -16.03 )
Ranked among companies with meaningful ROA (%) only.
GLPGF' s ROA (%) Range Over the Past 10 Years
Min: -18.65  Med: -6.10 Max: 11.91
Current: -16.03
-18.65
11.91
ROC (Joel Greenblatt) (%) -528.85
GLPGF's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. GLPGF: -528.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GLPGF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -247.33  Med: -69.33 Max: 9.71
Current: -528.85
-247.33
9.71
Revenue Growth (3Y)(%) -14.10
GLPGF's Revenue Growth (3Y)(%) is ranked lower than
66% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. GLPGF: -14.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GLPGF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.2  Med: 11.30 Max: 39.9
Current: -14.1
-19.2
39.9
EBITDA Growth (3Y)(%) 11.70
GLPGF's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. GLPGF: 11.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GLPGF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.6  Med: 11.70 Max: 103.6
Current: 11.7
-45.6
103.6
EPS Growth (3Y)(%) 2.80
GLPGF's EPS Growth (3Y)(%) is ranked higher than
60% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. GLPGF: 2.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GLPGF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.5  Med: 10.55 Max: 168.4
Current: 2.8
-69.5
168.4
» GLPGF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLPGF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.03
GLPGF's P/E(ttm) is ranked higher than
61% of the 390 Companies
in the Global Biotechnology industry.

( Industry Median: 26.50 vs. GLPGF: 23.03 )
Ranked among companies with meaningful P/E(ttm) only.
GLPGF' s P/E(ttm) Range Over the Past 10 Years
Min: 12.55  Med: 40.45 Max: 52.45
Current: 23.03
12.55
52.45
P/B 2.22
GLPGF's P/B is ranked higher than
55% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. GLPGF: 2.22 )
Ranked among companies with meaningful P/B only.
GLPGF' s P/B Range Over the Past 10 Years
Min: 2.03  Med: 6.54 Max: 8.49
Current: 2.22
2.03
8.49
P/S 21.01
GLPGF's P/S is ranked lower than
65% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.77 vs. GLPGF: 21.01 )
Ranked among companies with meaningful P/S only.
GLPGF' s P/S Range Over the Past 10 Years
Min: 6  Med: 19.35 Max: 28.91
Current: 21.01
6
28.91
Current Ratio 10.48
GLPGF's Current Ratio is ranked lower than
57% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. GLPGF: 10.48 )
Ranked among companies with meaningful Current Ratio only.
GLPGF' s Current Ratio Range Over the Past 10 Years
Min: 1.16  Med: 2.08 Max: 10.48
Current: 10.48
1.16
10.48
Quick Ratio 10.47
GLPGF's Quick Ratio is ranked lower than
55% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. GLPGF: 10.47 )
Ranked among companies with meaningful Quick Ratio only.
GLPGF' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 2.01 Max: 10.47
Current: 10.47
1.15
10.47
Days Sales Outstanding 70.34
GLPGF's Days Sales Outstanding is ranked higher than
60% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. GLPGF: 70.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLPGF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.58  Med: 114.23 Max: 142.1
Current: 70.34
55.58
142.1

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -2.79
GLPGF's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. GLPGF: -2.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GLPGF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3.78  Med: 0.80 Max: 29.75
Current: -2.79
-3.78
29.75

More Statistics

Revenue(Mil) $75
EPS $ 1.20
Beta-0.12
Short Percentage of Float0.00%
52-Week Range $19.10 - 62.11
Shares Outstanding(Mil)39.01

Analyst Estimate

Dec15
Revenue(Mil)
EPS($) -0.35
EPS without NRI($) -0.35

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GLPG.Belgium, GXE.Germany, GLPG.Netherlands, 0JXZ.UK, GLPG.USA,
Galapagos NV was founded in 1999. It is an integrated drug discovery company with capabilities from target discovery to clinical proof of concept. The company operates in two business divisions, R&D and Services. It also offers contract research services in the areas of in vitro, biology, analytics, among others. R&D operations specialize in the discovery and development of small molecules. Service operations offer target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. The Group's operations were located in Belgium, Croatia, France, Switzerland, The Netherlands and United Kingdom. The Group's R&D division is located in Belgium, Croatia, France and The Netherlands, with its service division operating in the remaining countries. Sales of goods consist of the sale of chemical compound libraries on a non-exclusive basis. The Group faces competition from contract research companies that may bring products and services to the market which are more competitive or affordable and which might hurt the position of the service operations.
» More Articles for OTCPK:GLPGF

Headlines

Articles On GuruFocus.com
The Best-Performing Non-S&P Stocks of 2015 Dec 30 2015 
Market Has Overreacted in Biogen Oct 14 2015 

More From Other Websites
Galapagos reports results with GLPG1205 in ulcerative colitis Jan 26 2016
Transparency notification - Gilead Sciences, Inc. holds 14.75% of Galapagos shares Jan 25 2016
Galapagos and Gilead complete closing of their global collaboration for filgotinib Jan 19 2016
Galapagos advances CF clinical development Jan 19 2016
Galapagos and Gilead cleared by US FTC to close their global partnership on filgotinib Jan 13 2016
Galapagos receives transparency notification from Wellington Management Group LLC Dec 23 2015
Galapagos creates new warrant plan 2015 Dec 23 2015
Galapagos and Gilead announce global partnership to develop filgotinib for the treatment of... Dec 17 2015
Filgotinib meets primary endpoint in phase 2 study in patients with moderate to severe Crohn's... Dec 07 2015
Hedge Funds Like What They See From Cyberonics, Inc. (CYBX) Nov 23 2015
Invitation to the Special Shareholders’ Meeting of Galapagos on 22 December 2015 Nov 23 2015
Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives €3.5 million milestone... Nov 20 2015
Galapagos reports third quarter 2015 cash position of €374 M Nov 13 2015
Galapagos builds on strong profile of filgotinib in 7 presentations at ACR 2015 Nov 09 2015
Dr. Christine Mummery appointed to Galapagos’ Board of Directors Nov 04 2015
Galapagos advances triple combination therapy in cystic fibrosis Oct 15 2015
Positive safety and tolerability for novel potentiator GLPG1837 Oct 09 2015
October 8, 2015 Galapagos to present promising findings in cystic fibrosis programs at NACFC 2015 Oct 08 2015
October 2, 2015 Galapagos raises €1.2 million through warrant exercises Oct 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK